On June 6, Abogen and Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (hereinafter referred to as "Ruijin Hospital") held a strategic cooperation agreement signing ceremony to further promote the application of mRNA technology in clinical settings, and accelerate the transformation of scientific research achievements and the development of new products.

Professor Shen Baiyong, Vice President of Ruijin Hospital, and Ms. Song Wenjie, Chief Medical Officer of Abogen Biosciences, signed the agreement on behalf of both parties. The signing was witnessed by Mr. Gu Haidong, Standing Committee Member of the Suzhou Municipal Party Committee and Executive Vice Mayor of Suzhou, Professor Ning Guang, Academician of the Chinese Academy of Engineering and President of Ruijin Hospital, and Dr. Ying Bo, Founder, Chairman, and CEO of Abogen Biosciences.

Also attending the event were several department director experts from Ruijin Hospital, Mr. Yin Jianguo, Chairman of Suzhou Industrial Park Biotech Development Co., Ltd., Dr. Yuan Jijun, President of Preclinical R&D at Abogen, and members of the R&D project team.

Vice Mayor Gu Haidong highly praised this strategic cooperation signing, stating in his speech that this signing is an important opportunity for the development of Suzhou's biopharmaceuticals industry and a significant exploration in paving the way for Suzhou's innovative development in biopharmaceuticals. Ruijin Hospital, as a nationally renowned tertiary comprehensive hospital in China, has strong capabilities, particularly with leading advantages nationwide in clinical applications. Today, Academician Ning Guang has led the expert directors from Ruijin Hospital to Suzhou, bringing development opportunities and confidence to the city’s biopharmaceutical enterprises. He also noted that Abogen possesses world-class advanced technology, setting a benchmark example for the industry and playing a demonstrative role. The Municipal Party Committee and the Municipal Government will fully support the future development of biopharmaceutical enterprises and comprehensively promote full cooperation between Suzhou's biopharmaceutical and healthcare companies and Ruijin Hospital, creating a win-win situation for all parties involved.

Academician Ning Guang stated in his speech that mRNA vaccines will experience explosive growth in the treatment of solid tumors in the future. The clinical safety of the technology has already been validated through the COVID-19 vaccine. Ruijin Hospital has made remarkable achievements in traditional medical techniques, and at the same time, it must continue to explore new technologies and fields, striving to stay at the forefront of the industry in mRNA technology. Academician Ning Guang said that the source of medical innovation is hospitals, while the main body of innovation is enterprises. This is his second visit to Abogen, and every time he visits, he can feel the company’s vibrant energy and the innovative capabilities of the younger generation. He said that the purpose of holding this ceremony at Abogen is to experience the innovative culture of the company and better introduce mRNA technology into Ruijin Hospital for comprehensive and open cooperation in areas such as cancer, blood diseases, and even autoimmune diseases—daring to break through and being bold in innovation.

Dr. Ying Bo stated that the outstanding medical talent team and advanced medical equipment and technology of Ruijin Hospital have provided a solid application and practice platform for the development of new technologies at Abogen. Currently, both parties have already launched cooperation in multiple fields such as oncology, with more project clinical trials about to begin. Dr. Ying Bo said that this strategic cooperation in cutting-edge fields is not only of strategic significance to Ruijin Hospital and Abogen but will also further strengthen Suzhou's influence in the biopharmaceutical field across China and even globally, demonstrating leadership, flagship, and exemplary effects. Innovation in the biopharmaceutical field is a mission bestowed upon us by this era.

The successful signing of this strategic cooperation agreement marks a new chapter of comprehensive and deepened collaboration between Ruijin Hospital and Abogen Biosciences. Both parties will actively leverage their respective resources and strengths to continuously promote the practical application of mRNA technology, providing innovative treatment solutions for critical diseases and bringing hope and good news to more patients.

During the period, Vice Mayor Gu Haidong, Academician Ning Guang, and a group of experts and directors from Ruijin Hospital, accompanied by Dr. Ying Bo, Ms. Song Wenjie, and Dr. Yuan Jijun, visited the Abogen Research and Development Center. They gained an in-depth understanding of the company's development history and research progress, and inquired in detail about and highly praised the design, construction, and operation of the company’s fully automated mRNA equipment.

About Us

Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company specializing in the research and development of messenger ribonucleic acid (mRNA) drugs. The company possesses industry-leading, proprietary mRNA and nanodelivery technology platforms, making it one of the few mRNA drug developers in China with complete value chain capabilities, covering every aspect from mRNA design, formulation development, to large-scale production. Abogen has established a robust product pipeline spanning multiple fields, including infectious disease prevention and treatment, cancer immunotherapy, and protein replacement therapies, featuring the mRNA COVID-19 vaccine among others. In September 2022, ARCoV, Abogen's mRNA vaccine for COVID-19, received emergency use authorization in Indonesia, becoming the first Chinese-produced mRNA vaccine to be approved for overseas use.

Edition

Authority

Sound

Ming

All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reproduced can contact us (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and do not represent the position of this website.